IDEAS home Printed from https://ideas.repec.org/a/eee/hepoli/v83y2007i2-3p257-267.html
   My bibliography  Save this article

A national hypertension treatment program in Germany and its estimated impact on costs, life expectancy, and cost-effectiveness

Author

Listed:
  • Gandjour, Afschin
  • Stock, Stephanie

Abstract

No abstract is available for this item.

Suggested Citation

  • Gandjour, Afschin & Stock, Stephanie, 2007. "A national hypertension treatment program in Germany and its estimated impact on costs, life expectancy, and cost-effectiveness," Health Policy, Elsevier, vol. 83(2-3), pages 257-267, October.
    • Handle: RePEc:eee:hepoli:v:83:y:2007:i:2-3:p:257-267
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/S0168-8510(07)00020-6
    Download Restriction: Full text for ScienceDirect subscribers only
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Afschin Gandjour & Karl Wilhelm Lauterbach, 2003. "When Is It Worth Introducing a Quality Improvement Program? A Mathematical Model," Medical Decision Making, , vol. 23(6), pages 518-525, November.
    2. Joel Tsevat & Lee Goldman & Jane R. Soukup & Gervasio A. Lamas & Kathleen F. Connors & Carole C. Chapin & Thomas H. Lee, 1993. "Stability of Time-tradeoff Utilities in Survivors of Myocardial Infarction," Medical Decision Making, , vol. 13(2), pages 161-165, June.
    3. Christiane Gasse & Hans-Werner Hense & Jutta Stieber & Angela Döring & Angela Liese & Günther Heller & Ulrich Keil, 2002. "Factors associated with differences in antihypertensive drug treatment: Results from the MONICA Augsburg Population Surveys 1989/90 and 1994/95," International Journal of Public Health, Springer;Swiss School of Public Health (SSPH+), vol. 47(2), pages 128-139, March.
    4. Afschin Gandjour & Karl Wilhelm Lauterbach, 2005. "How Much Does It Cost to Change the Behavior of Health Professionals? A Mathematical Model and an Application to Academic Detailing," Medical Decision Making, , vol. 25(3), pages 341-347, May.
    5. Frank A. Sonnenberg & J. Robert Beck, 1993. "Markov Models in Medical Decision Making," Medical Decision Making, , vol. 13(4), pages 322-338, December.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Robert L. Herrick & Steven G. Buchberger & Robert M. Clark & Margaret Kupferle & Regan Murray & Paul Succop, 2012. "A Markov Model To Estimate Salmonella Morbidity, Mortality, Illness Duration, And Cost," Health Economics, John Wiley & Sons, Ltd., vol. 21(10), pages 1169-1182, October.
    2. Eberhard Wille & Jürgen Scholze & Eduardo Alegria & Claudio Ferri & Sue Langham & Warren Stevens & David Jeffries & Kerstin Uhl-Hochgraeber, 2011. "Modelling the costs of care of hypertension in patients with metabolic syndrome and its consequences, in Germany, Spain and Italy," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 12(3), pages 205-218, June.
    3. Dirk Mueller & Afschin Gandjour, 2008. "Cost effectiveness of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women," Applied Health Economics and Health Policy, Springer, vol. 6(2), pages 113-135, July.
    4. Afschin Gandjour, 2010. "A model to predict the cost‐effectiveness of disease management programs," Health Economics, John Wiley & Sons, Ltd., vol. 19(6), pages 697-715, June.
    5. Dirk Mueller & Eva Weyler & Afschin Gandjour, 2008. "Cost Effectiveness of the German Screen-and-Treat Strategy for Postmenopausal Osteoporosis," PharmacoEconomics, Springer, vol. 26(6), pages 513-536, June.
    6. Daniel M. Sugrue & Thomas Ward & Sukhvir Rai & Phil McEwan & Heleen G. M. Haalen, 2019. "Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design," PharmacoEconomics, Springer, vol. 37(12), pages 1451-1468, December.
    7. Dirk Mueller & Afschin Gandjour, 2011. "Cost effectiveness of secondary vs tertiary prevention for post-menopausal osteoporosis," Applied Health Economics and Health Policy, Springer, vol. 9(4), pages 259-273, July.
    8. Rachel A. Elliott & Lukasz Tanajewski & Georgios Gkountouras & Anthony J. Avery & Nick Barber & Rajnikant Mehta & Matthew J. Boyd & Asam Latif & Antony Chuter & Justin Waring, 2017. "Cost Effectiveness of Support for People Starting a New Medication for a Long-Term Condition Through Community Pharmacies: An Economic Evaluation of the New Medicine Service (NMS) Compared with Normal," PharmacoEconomics, Springer, vol. 35(12), pages 1237-1255, December.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Afschin Gandjour, 2010. "A model to predict the cost‐effectiveness of disease management programs," Health Economics, John Wiley & Sons, Ltd., vol. 19(6), pages 697-715, June.
    2. Afschin Gandjour, 2010. "Investment in quality improvement: how to maximize the return," Health Economics, John Wiley & Sons, Ltd., vol. 19(1), pages 31-42, January.
    3. Bart Heeg & Ron Peters & Marc Botteman & Ben Hout, 2007. "Long-Term Clopidogrel Therapy in Patients Receiving Percutaneous Coronary Intervention," PharmacoEconomics, Springer, vol. 25(9), pages 769-782, September.
    4. Peter Lindgren & Thomas Kahan & Neil Poulter & Martin Buxton & Patrick Svarvar & Björn Dahlöf & Bengt Jönsson, 2007. "Utility loss and indirect costs following cardiovascular events in hypertensive patients: the ASCOT health economic substudy," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 8(1), pages 25-30, March.
    5. Mason, J.E. & Denton, B.T. & Shah, N.D. & Smith, S.A., 2014. "Optimizing the simultaneous management of blood pressure and cholesterol for type 2 diabetes patients," European Journal of Operational Research, Elsevier, vol. 233(3), pages 727-738.
    6. Malek B Hannouf & Chander Sehgal & Jeffrey Q Cao & Joseph D Mocanu & Eric Winquist & Gregory S Zaric, 2012. "Cost-Effectiveness of Adding Cetuximab to Platinum-Based Chemotherapy for First-Line Treatment of Recurrent or Metastatic Head and Neck Cancer," PLOS ONE, Public Library of Science, vol. 7(6), pages 1-9, June.
    7. Bärnighausen, Till & Bloom, David E., 2009. ""Conditional scholarships" for HIV/AIDS health workers: Educating and retaining the workforce to provide antiretroviral treatment in sub-Saharan Africa," Social Science & Medicine, Elsevier, vol. 68(3), pages 544-551, February.
    8. de Wit, G.Ardine & Ramsteijn, Paul G & de Charro, Frank Th, 1998. "Economic evaluation of end stage renal disease treatment," Health Policy, Elsevier, vol. 44(3), pages 215-232, June.
    9. Afschin Gandjour & Eva-Julia Weyler, 2006. "Cost-effectiveness of referrals to high-volume hospitals: An analysis based on a probabilistic Markov model for hip fracture surgeries," Health Care Management Science, Springer, vol. 9(4), pages 359-369, November.
    10. Malek Ebadi & Raha Akhavan-Tabatabaei, 2021. "Personalized Cotesting Policies for Cervical Cancer Screening: A POMDP Approach," Mathematics, MDPI, vol. 9(6), pages 1-20, March.
    11. Mark Sculpher & David Torgerson & Ron Goeree & Bernie O'Brien, 1999. "A critical structured review of economic evaluations of interventions for the prevention and treatment of osteoporosis," Working Papers 169chedp, Centre for Health Economics, University of York.
    12. F. Tomini & F. Prinzen & A. D. I. Asselt, 2016. "A review of economic evaluation models for cardiac resynchronization therapy with implantable cardioverter defibrillators in patients with heart failure," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(9), pages 1159-1172, December.
    13. Chisholm, Orin & Sharry, Patrick & Phillips, Lawrence, 2022. "Multi-criteria decision analysis for benefit-risk analysis by national regulatory authorities," LSE Research Online Documents on Economics 114407, London School of Economics and Political Science, LSE Library.
    14. Franck Maunoury & Aurore Clément & Chizoba Nwankwo & Laurie Levy-Bachelot & Armand Abergel & Vincent Di Martino & Eric Thervet & Isabelle Durand-Zaleski, 2018. "Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France," PLOS ONE, Public Library of Science, vol. 13(3), pages 1-20, March.
    15. Stephen G. Pauker & John B. Wong, 2005. "The Influence of Influence Diagrams in Medicine," Decision Analysis, INFORMS, vol. 2(4), pages 238-244, December.
    16. K Cooper & S C Brailsford & R Davies, 2007. "Choice of modelling technique for evaluating health care interventions," Journal of the Operational Research Society, Palgrave Macmillan;The OR Society, vol. 58(2), pages 168-176, February.
    17. F. R. Rolli & M. Ruggeri & F. Kheiraoui & C. Drago & M. Basile & C. Favaretti & A. Cicchetti, 2018. "Economic evaluation of Zepatier for the management of HCV in the Italian scenario," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(9), pages 1365-1374, December.
    18. Nicholas Graves & Mary Courtney & Helen Edwards & Anne Chang & Anthony Parker & Kathleen Finlayson, 2009. "Cost-Effectiveness of an Intervention to Reduce Emergency Re-Admissions to Hospital among Older Patients," PLOS ONE, Public Library of Science, vol. 4(10), pages 1-9, October.
    19. Jan Jürgensen & Wolfgang Arns & Bastian Haß, 2010. "Cost-effectiveness of immunosuppressive regimens in renal transplant recipients in Germany: a model approach," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(1), pages 15-25, February.
    20. Douglas K. Owens, 2002. "Analytic Tools for Public Health Decision Making," Medical Decision Making, , vol. 22(1_suppl), pages 3-10, September.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:hepoli:v:83:y:2007:i:2-3:p:257-267. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu or the person in charge (email available below). General contact details of provider: http://www.elsevier.com/locate/healthpol .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.